ACT in action.

Blanca Morales’ son was sick for four months before she started asking for a transplant, but stricter FDA guidelines around stool banks made the treatment harder to find.

ACT is proud to announce that our collaboration with the University of Minnesota Microbiota Therapeutics Program is partnering with OpenBiome to distribute Intestinal Microbiota Therapeutics to patients suffering from recurrent C. difficile infections. To date, we have treated over 1,500 recurrent C. difficile patients. Now, utilizing OpenBiome’s network of clinical providers across the country, we aim to treat thousands more.

The Council of Canadian Acadamies comprehensive assessment of the current and future impact of antimicrobial resistance (AMR) predicts that the rate of resistance will grow from 26% in 2018 to 40% in 2050. The CCR also analyzes the implications of AMR to public health, the economy, industry & quality of life.

Clostridium difficile infection (CDI) is the most common hospital-acquired infection in the U.S., and has become a global public health issue. The infection can cause a range of gastrointestinal symptoms, which estimates suggest ultimately result in nearly 30,000 deaths every year in the U.S. alone. While the most significant risk factor for CDI is antibiotic treatment, studies in mice by a team at Vanderbilt University School of Medicine now provide new evidence that connects the use of common nonsteroidal anti-inflammatory drugs (NSAID) with increased severity of CDI. Their results also point to the molecular mechanisms that underpin this link.

(CNN) A 49-year-old Pennsylvania woman showed the presence of a rare kind of E. coli infection, the first known case of its kind in the United States. It is a superbug that is resistant to many antibiotics, even Colistin, which doctors use as a last resort when other antibiotics fail.